Cargando…

Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study

Bacille Calmette-Guérin (BCG), the only currently licenced tuberculosis vaccine, may exert beneficial non-specific effects (NSE) in reducing infant mortality. We conducted a randomised controlled clinical study in healthy UK adults to evaluate potential NSE using functional in-vitro growth inhibitio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilkie, Morven, Tanner, Rachel, Wright, Daniel, Lopez Ramon, Raquel, Beglov, Julia, Riste, Michael, Marshall, Julia L., Harris, Stephanie A., Bettencourt, Paulo J. G., Hamidi, Ali, van Diemen, Pauline M., Moss, Paul, Satti, Iman, Wyllie, David, McShane, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096342/ https://www.ncbi.nlm.nih.gov/pubmed/35552463 http://dx.doi.org/10.1038/s41598-022-11748-x

Ejemplares similares

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
por: Manjaly Thomas, Zita-Rose, et al.
Publicado: (2019)

Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination
por: Bitencourt, Julia, et al.
Publicado: (2022)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults
por: Minhinnick, Alice, et al.
Publicado: (2016)

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults
por: Riste, Michael, et al.
Publicado: (2021)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults
por: Wilkie, Morven, et al.
Publicado: (2020)

Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in Combination
por: Harris, Stephanie A., et al.
Publicado: (2014)

Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity
por: Minhinnick, Alice, et al.
Publicado: (2016)

Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines
por: Harris, Stephanie A., et al.
Publicado: (2018)

Gene Expression and Cytokine Profile Correlate With Mycobacterial Growth in a Human BCG Challenge Model
por: Matsumiya, Magali, et al.
Publicado: (2015)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial
por: Satti, Iman, et al.
Publicado: (2014)

Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants
por: Satti, Iman, et al.
Publicado: (2022)

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
por: Sheehan, Sharon, et al.
Publicado: (2015)

The Humoral Immune Response to BCG Vaccination
por: Tanner, Rachel, et al.
Publicado: (2019)

TB vaccine development: where are we and why is it so difficult?
por: Wilkie, Morven E M, et al.
Publicado: (2015)

Editorial Commentary: Understanding BCG Is the Key to Improving It
por: McShane, Helen
Publicado: (2014)

T-cell activation is an immune correlate of risk in BCG vaccinated infants
por: Fletcher, Helen A., et al.
Publicado: (2016)

Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants
por: Fletcher, Helen A., et al.
Publicado: (2016)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
por: Wajja, Anne, et al.
Publicado: (2017)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery()
por: Meyer, Joel, et al.
Publicado: (2013)

Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2009)

Optimisation, harmonisation and standardisation of the direct mycobacterial growth inhibition assay using cryopreserved human peripheral blood mononuclear cells
por: Tanner, Rachel, et al.
Publicado: (2019)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2011)

The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells
por: Tanner, Rachel, et al.
Publicado: (2021)

Preclinical Development of an In Vivo BCG Challenge Model for Testing Candidate TB Vaccine Efficacy
por: Minassian, Angela M., et al.
Publicado: (2011)

A Human Challenge Model for Mycobacterium tuberculosis Using Mycobacterium bovis Bacille Calmette-Guérin
por: Minassian, Angela M., et al.
Publicado: (2012)

A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates
por: Tanner, Rachel, et al.
Publicado: (2021)

Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis()
por: Poyntz, Hazel C., et al.
Publicado: (2014)

Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection
por: O’Shea, Matthew K., et al.
Publicado: (2018)

Development of a BCG challenge model for the testing of vaccine candidates against tuberculosis in cattle
por: Villarreal-Ramos, Bernardo, et al.
Publicado: (2014)

Identification and Evaluation of Novel Protective Antigens for the Development of a Candidate Tuberculosis Subunit Vaccine
por: Stylianou, Elena, et al.
Publicado: (2018)

Assay optimisation and technology transfer for multi-site immuno-monitoring in vaccine trials
por: Smith, Steven G., et al.
Publicado: (2017)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: A phase I clinical trial
por: Rowland, Rosalind, et al.
Publicado: (2013)

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response
por: Matsumiya, Magali, et al.
Publicado: (2014)

Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
por: Tanner, Rachel, et al.
Publicado: (2020)

Induction and maintenance of a phenotypically heterogeneous lung tissue-resident CD4(+) T cell population following BCG immunisation
por: Bull, Naomi C., et al.
Publicado: (2018)

A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis
por: Zelmer, Andrea, et al.
Publicado: (2016)

Dissecting the Mycobacterium bovis BCG Response to Macrophage Infection to Help Prioritize Targets for Anti-Tuberculosis Drug and Vaccine Discovery
por: Medley, Jamie, et al.
Publicado: (2022)

Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A
por: Harris, Stephanie A., et al.
Publicado: (2014)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-β1
por: Fletcher, Helen A., et al.
Publicado: (2008)

Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease—The Shifting Treatment Paradigm
por: Wilkie, Morven, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_isp1jo54gj50v99tb7p0b9rmn7